• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
FDA-approved anti-obesity GLP-1 RA prescription trends among adolescents

FDA-approved anti-obesity GLP-1 RA prescription trends among adolescents

by Truveta Research | Jun 3, 2025 | Research, Research Insights

In collaboration with Reuters, Truveta Research explored trends in FDA-approved anti-obesity GLP-1 RA prescriptions among adolescents. Among the 1,265,399 adolescents (aged 12-17 years) in this study, the average rate of first-time AOM semaglutide prescriptions was...
ASCO 2025: Development and validation of machine learning risk prediction models for detection of early-onset colorectal cancer

ASCO 2025: Development and validation of machine learning risk prediction models for detection of early-onset colorectal cancer

by Truveta staff | May 30, 2025 | Research, Research Insights

Authors: Wilson Lau, PhD ⊕Truveta, Inc, Bellevue, WA,, Youngwon Kim, PhD ⊕Truveta, Inc, Bellevue, WA, Sravanthi Paras, MD ⊕Swedish Medical Center, Seattle, WA, Md Enamul Haque, PhD ⊕Truveta, Inc, Bellevue, WA,, Sara Daraei, PhD ⊕Truveta, Inc, Bellevue, WA, Rajesh Rao,...
ASCO 2025: Changes in colorectal cancer screening and detection following USPSTF expanded recommendations

ASCO 2025: Changes in colorectal cancer screening and detection following USPSTF expanded recommendations

by Truveta Research | May 30, 2025 | Research, Research Insights

Authors: Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Jennifer Liang, MD ⊕Truveta, Inc, Bellevue, WA, Keenan Robbins, MBBS ⊕Washington University...
Truveta Data analysis shows improved outcomes with Impella support in high-risk heart procedures

Truveta Data analysis shows improved outcomes with Impella support in high-risk heart procedures

by Truveta staff | May 21, 2025 | Research

A recent analysis using Truveta Data reveals that patients undergoing high-risk, non-emergency heart procedures (percutaneous coronary intervention, or PCI) with support from the Impella heart pump had better outcomes than those supported with an intra-aortic balloon...
Evaluating recent trends in early measles vaccinations in Texas

Evaluating recent trends in early measles vaccinations in Texas

by Truveta Research | May 16, 2025 | Research, Research Insights

Among children in Texas receiving a first measles vaccine prior to two years of life: In March and April 2025, 20.1% of all first measles vaccines were administered to children early (6-11 months). This is 11.5-fold higher than in 2019, when there were international...
ISPOR 2025: Trends in the prescribing and dispensing of GLP-1 anti-obesity medications among adults with cardiovascular disease

ISPOR 2025: Trends in the prescribing and dispensing of GLP-1 anti-obesity medications among adults with cardiovascular disease

by Truveta Research | May 14, 2025 | Research, Research Insights

Authors: Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Karthik Murugiah, MBBS, MHS ⊕Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven,...
« Older Entries
Next Entries »

Share this


Recent posts

  • Real-world survival outcomes for CRT and CCM therapies align with landmark trials
  • Understanding the potential impact of the upcoming ACIP vote on thimerosal-containing influenza vaccines
  • Biosimilar use is on the rise – but 1 in 8 patients return to Humira

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Our website uses cookies to ensure you have the best experience.AcceptPrivacy notice